A Phase 2 interventional study of LYS006 20 mg and LYS006 2 mg in Inflammatory Acne, sponsored by Novartis Pharmaceuticals. Completed at 17 sites in 6 countries. Open to participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2023-08-31.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 374 studies in Acne Vulgaris with a site in United States — 20 open to participants now, 29 under way, 2 of them phase 3. Acne Vulgaris · United States.
Among the 374 studies in Acne Vulgaris with a site in United States, this one is the 187th largest by enrollment of the 354 interventional ones that give a count, is one of 20 that started in 2018, is one of 65 in phase 2, and was the 249th registered.
795 studies on the registry are indexed under Acne Vulgaris; 96 are open to participants now.
Browse Acne Vulgaris studies →20 of the 374 studies in Acne Vulgaris with a site in United States are open now. Recruiting first, the newest first:
Weill Medical College of Cornell University · Sites in United States
Ages 18+
Sagimet Biosciences Inc. · Sites in United States
Ages 12+
Integrative Skin Science and Research · Sites in United States
Ages 9+ · Healthy volunteers
Bausch Health Americas, Inc. · Sites in United States
Ages 9–11
Sanofi Pasteur, a Sanofi Company · Sites in United States
Ages 18–45
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 48 Acne Vulgaris studies recruiting now, 17 (35%) set no upper age limit and 30 (63%) stop at 75 or younger; 21 take children under 18; 17 take healthy volunteers.
This study: 18 Years to 45 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
374 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 58 · Phase 2 82 · Phase 3 82 · Phase 4 72
First in 2002; this study’s year is marked. 20 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 66 is close to the median of 70 across 676 interventional studies indexed under Acne Vulgaris.
Median enrollment 78 across the 354 interventional studies, 59 across the 19 observational. Of the 323 that completed or were terminated, 189 (59%) have results posted.
This tab as a report to print or save as PDF → With an account.
287 of 374 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,721 studies on the registry; 222 are open to participants now.
Of its 586 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
Novartis has 2 studies filed under Acne Vulgaris — fewer than ten, so there is no comparison to draw.
10 of the studies in Acne Vulgaris with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07863193Phase 3Sagimet Biosciences Inc.Phase 3 Study of Denifanstat in Participants With Moderate to Severe Acne (AURORA) | 2027-08 |
| NCT06315166PollogenStudy on Using Radiofrequency to Treat Moderate to Severe Acne | 2026-12 |
| NCT02713607University of California, DavisLipidome and Microbiome Profile of Acne | 2027-01 |
| NCT07946250BrocShot IncA Clinical Trial to Evaluate the Effects of Broc Shot Capsules on Skin Appearance and Comfort in Adults With Reactive, Blemish-Prone, or Hormonally Affected Skin | 2027-01 |
| NCT06989840Sagimet Biosciences Inc.Phase 1 Study to Evaluate the Safety, Tolerability, PK, and PD of TVB-3567 in Healthy Participants With or Without Acne | 2027-01 |
Add all 10 to your calendar (.ics) → With an account.
Among the 374 studies in Acne Vulgaris with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The main purpose of this study is to assess preliminary efficacy and safety of LYS006 in patients with moderate to severe inflammatory acne and to determine if LYS006 has an adequate clinical profile for further clinical development.
This was a randomized, placebo-controlled, subject- and investigator-blinded, multicenter, nonconfirmatory, parallel group, and proof-of-concept study in adult patients with moderate to severe inflammatory acne. After an initial screening period (up to 4 weeks), subjects were treated with LYS006 or matching placebo for 12 consecutive weeks to assess preliminary clinical efficacy, safety, and tolerability in the targeted subject population. At the beginning of the treatment period, subjects were randomized to one of three treatment groups, i.e., LYS006 20 mg twice daily (BID), LYS006 2 mg BID or matching placebo in a 3:1:3 ratio.
After treatment period completion, all subjects entered a post-treatment safety follow-up period of 4 weeks without study drug administration. The maximum duration of study participation was 20 weeks. Study completion was defined as when the last subject completed his/her study completion visit, and any repeat assessments associated with this visit were documented and followed-up appropriately by the investigator, or in the event of an early study termination decision, the date of that decision.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LYS006, 20 mg, orally, twice daily (BID), for 12 weeks
Drug: LYS006 20 mg
LYS006, 2 mg, orally, BID, for 12 weeks
Drug: LYS006 2 mg
Matching placebo, orally, BID, for 12 weeks
Drug: Placebo
LYS006 20 mg, capsules, oral administration, BID, for 12 weeks
LYS006 2 mg, capsules, oral administration, BID, for 12 weeks
Matching placebo, capsules, oral administration, BID, for 12 weeks
Total Inflammatory Lesion Count
Inflammatory facial lesion count included papules, pustules, and nodules. The natural log transformed inflammatory facial lesion count up to Week 12 was analyzed using a Bayesian mixed effect model for repeated measurements (MMRM). Values estimated from the model at Week 12 are presented in the table. Posterior geometric mean and 90% credible intervals in each group are presented.
Time frame: Week 12
Participants took part in 18 investigative sites in 6 countries.
| Milestone | LYS006 20 mg BID | LYS006 2 mg BID | Placebo BID |
|---|---|---|---|
| Started | 26 | 11 | 29 |
| Completed treatment period | 23 | 9 | 24 |
| Pharmacodynamic (pd) analysis set | 24 | 11 | 28 |
| Completed | 20 | 9 | 23 |
| Not completed | 6 | 2 | 6 |
| Withdrew: Adverse event | 1 | 1 | 1 |
| Withdrew: Lost to follow-up | 2 | 0 | 2 |
| Withdrew: Physician decision | 1 | 0 | 0 |
| Withdrew: Subject/guardian decision | 2 | 1 | 3 |
Inflammatory facial lesion count included papules, pustules, and nodules. The natural log transformed inflammatory facial lesion count up to Week 12 was analyzed using a Bayesian mixed effect model for repeated measurements (MMRM). Values estimated from the model at Week 12 are presented in the table. Posterior geometric mean and 90% credible intervals in each group are presented.
| lesions | LYS006 20 mg BID | LYS006 2 mg BID | Placebo BID |
|---|---|---|---|
| Total Inflammatory Lesion Count | 18.55 (14.16 to 24.32) | 24.51 (16.35 to 36.94) | 20.04 (15.42 to 26.13) |
Collected over Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 128 days. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| LYS006 20 mg BID | 0/26 (0%) | 0/26 (0%) | 10/26 (38.5%) |
| LYS006 2 mg BID | 0/11 (0%) | 0/11 (0%) | 8/11 (72.7%) |
| Placebo BID | 0/29 (0%) | 0/29 (0%) | 16/29 (55.2%) |
| Total | 0/66 (0%) | 0/66 (0%) | 34/66 (51.5%) |
| Event | LYS006 20 mg BID | LYS006 2 mg BID | Placebo BID | Total |
|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 3/26 | 3/11 | 3/29 | 9/66 |
| Abdominal painGastrointestinal disorders | 0/26 | 2/11 | 0/29 | 2/66 |
| Urinary tract infectionInfections and infestations | 0/26 | 2/11 | 2/29 | 4/66 |
| HeadacheNervous system disorders | 0/26 | 2/11 | 3/29 | 5/66 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 0/26 | 2/11 | 0/29 | 2/66 |
| Crystal urine presentInvestigations | 2/26 | 0/11 | 4/29 | 6/66 |
| Blood creatine phosphokinase increasedInvestigations | 2/26 | 1/11 | 3/29 | 6/66 |
| TinnitusEar and labyrinth disorders | 0/26 | 1/11 | 0/29 | 1/66 |
| DiarrhoeaGastrointestinal disorders | 0/26 | 1/11 | 0/29 | 1/66 |
| NauseaGastrointestinal disorders | 1/26 | 1/11 | 1/29 | 3/66 |
| Age, Continuous(years) | LYS006 20 mg BID | LYS006 2 mg BID | Placebo BID | Total |
|---|---|---|---|---|
| Mean | 23.2 ± 6.89 | 24.5 ± 6.23 | 25.0 ± 5.40 | 24.2 ± 6.13 |
| Sex: Female, Male(Participants) | LYS006 20 mg BID | LYS006 2 mg BID | Placebo BID | Total |
|---|---|---|---|---|
| Female | 16 | 8 | 22 | 46 |
| Male | 10 | 3 | 7 | 20 |
| Race/Ethnicity, Customized(participants) | LYS006 20 mg BID | LYS006 2 mg BID | Placebo BID | Total |
|---|---|---|---|---|
| Asian | 1 | 1 | 1 | 3 |
| Black or African American | 2 | 1 | 6 | 9 |
| Other | 2 | 1 | 6 | 9 |
| White | 21 | 8 | 16 | 45 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Ran from Sep 2018 to primary completion in Feb 2022, 41 months.
Results were first posted in Mar 2023, 1 year after primary completion.
Of 29 industry-sponsored phase 2 interventional studies under Acne Vulgaris, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 15. This study's 41 months is above that.
Counting every sponsor, half of 37 studies reached it within 9 months; a quarter within 6 and three quarters within 15.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: LYS-006